Results 81 to 90 of about 171,342 (310)

Targeted modulation of IGFL2‐AS1 reveals its translational potential in cervical adenocarcinoma

Molecular Oncology, EarlyView.
Cervical adenocarcinoma patients face worse outcomes than squamous cell carcinoma counterparts despite similar treatment. The identification of IGFL2‐AS1's differential expression provides a molecular basis for distinguishing these histotypes, paving the way for personalized therapies and improved survival in vulnerable populations globally.
Ricardo Cesar Cintra, Lucca Paolo Hsu Helmich, Daniel Rodrigues de Bastos, Laura Sichero, Patrícia Savio de Araujo‐Souza, Fabio Passetti, Luisa Lina Villa   +6 more
wiley   +1 more source

Effectiveness of Transcatheter Arterial Embolization in Locally Advanced Triple- Negative Breast Cancer Resistant to Neoadjuvant Chemotherapy: A Case Report

Journal of the Korean Society of Radiology
A 74-year-old woman was diagnosed with locally advanced invasive ductal carcinoma of the right breast, which was confirmed as triple-negative breast cancer (TNBC) by immunohistochemical analysis. Multiple ipsilateral axillary lymph node metastases were
Seo Ha Park, Keong Won Yun, Ga Young Yoon, Youngjong Cho, Seungeun Kim   +4 more
doaj   +1 more source

Diagnostic, Prognostic and Therapeutic Value of Gene Signatures [PDF]

, 2012
Gene expression studies have revealed diagnostic profiles and upregulation of specific pathways in many solid tumors. Some gene-expression signatures are already used as predictors of relapse in early breast cancer patients.
Iacobelli, S, Iacobelli, S, Iovanna, J, Iovanna, J, Russo, A, Russo, A   +5 more
core   +1 more source

COMP–PMEPA1 axis promotes epithelial‐to‐mesenchymal transition in breast cancer cells

Molecular Oncology, EarlyView.
This study reveals that cartilage oligomeric matrix protein (COMP) promotes epithelial‐to‐mesenchymal transition (EMT) in breast cancer. We identify PMEPA1 (protein TMEPAI) as a novel COMP‐binding partner that mediates EMT via binding to the TSP domains of COMP, establishing the COMP–PMEPA1 axis as a key EMT driver in breast cancer.
Konstantinos S. Papadakos, Gilar Gorji‐bahri, Lejla Gradjan, Julia Zajac, Kacper Gil, Yvonne Thokozile Nduku, Anna M. Blom   +6 more
wiley   +1 more source

Keratin 19 as a prognostic marker and contributing factor of metastasis and chemoresistance in high‐grade serous ovarian cancer

Molecular Oncology, EarlyView.
Keratin 19 (KRT19) is overexpressed in high‐grade serous ovarian cancer with high levels of Kallikrein‐related peptidases (KLK) 4–7 and is associated with poor survival. In vivo analyses demonstrate that elevated KRT19 increases peritoneal tumour burden.
Sophia Bielesch, Isabel Vogel, Sina Nokodian, Johanna Moeller, Antonia Blechschmidt, Vicky Hecht, Vanessa Kuentzel, Katharina Thiedig, Melissa Schwab, Oliver Schilling, Holger Bronger, Marion Kiechle, Viktor Magdolen, Tobias Dreyer   +13 more
wiley   +1 more source

An Unusual Presentation of Synchronous Breast Cancer and Skin Malignancy in a Patient with Lynch Syndrome: A Case Report and Review of the Literature

Biomedicines
Background: Lynch syndrome is an autosomal dominant condition that leads to an increased risk of many neoplasms. In the United Kingdom, NICE recommends that patients with colorectal and endometrial cancer should be tested for Lynch syndrome.
Maiar Elghobashy, Michael Siafakas, Mona Elshafie, Rahul Hejmadi, Naren N. Basu, Abeer M. Shaaban   +5 more
doaj   +1 more source

Sebaceous breast carcinoma

Autopsy and Case Reports, 2022
Breast sebaceous carcinoma is one of the rarest breast neoplasms, with less than 30 cases reported worldwide. Due to the rarity, the new WHO classification of breast tumors grouped these tumors among the ductal carcinoma. A detailed description of these
Natália Nobre de Alencar, Diego Agra de Souza, Alexandre Alves Lourenço, Raimunda Ribeiro da Silva   +3 more
doaj  

Experience in treating BRCA-associated breast cancer. The BRCA-history of a family

Медицинский совет, 2021
Breast cancer (BC) is the most common cancer and the primary cause of cancer death. About 5 to 10% of breast cancer cases have a hereditary background. BRCA-related breast cancer is characterized by more aggressive phenotype than sporadic breast cancer ...
A. V. Sultanbaev, K. V. Menshikov, A. F. Nasretdinov, A. A. Izmailov, S. I. Musin, I. A. Menshikova, A. V. Chashchin, N. I. Sultanbaeva   +7 more
doaj   +1 more source

MTOR cross-talk in cancer and potential for combination therapy [PDF]

, 2018
The mammalian Target of Rapamycin (mTOR) pathway plays an essential role in sensing and integrating a variety of exogenous cues to regulate cellular growth and metabolism, in both physiological and pathological conditions.
Bazzichetto, C., Bria, E., Ciuffreda, L., Cognetti, F., Conciatori, F., Falcone, I., Milella, M, Pilotto, S.   +7 more
core   +3 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source